Active Ingredient History

NOW
  • Now
Butorphanol is a synthetic opioid agonist-antagonist analgesic with a pharmacological and therapeutic profile that has been well established since its launch as a parenteral formulation in 1978. The introduction of a transnasal formulation of butorphanol represents a new and noninvasive presentation of an analgesic for moderate to severe pain. This route of administration bypasses the gastrointestinal tract, and this is an advantage for a drug such as butorphanol that undergoes significant first-pass metabolism after oral administration. The onset of action and systemic bioavailability of butorphanol following transnasal delivery are similar to those after parenteral administration. Butorphanol blocks pain impulses at specific sites in the brain and spinal cord. Butorphanol has agonistic activity at the κ-receptor and antagonistic activity at the μ-receptor. It also exhibits partial agonistic activity at the σ-receptor.   NCATS

  • SMILES: Oc1ccc2C[C@H]3N(CC4CCC4)CC[C@@]5(CCCC[C@@]35O)c2c1
  • InChIKey: IFKLAQQSCNILHL-QHAWAJNXSA-N
  • Mol. Mass: 327.47
  • ALogP: 3.37
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

United States

$9.5867 - $14.2715
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

(-)-17-(cyclobutylmethyl)morphinan-3,14-diol | bc 2627 | bc-2627 | butorfanol | butorphanol | (-)-butorphanol | butorphanol tartrate | butorphanolum | levo-bc-2627 | levo-bc-2627 tartrate | (-)-n-cyclobutylmethyl-3,14-dihydroxymorphinan | stadol | stadol ns | torbugesic | torbutrol

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue